Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab-Grown 'Mini Tumors' could personalize pancreatic cancer care

NCT ID NCT06666803

Knowledge-focused Sponsor: IHU Strasbourg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to grow miniature versions of pancreatic tumors, called organoids, from small biopsy samples taken during routine endoscopic procedures. Researchers will check if these organoids match the genetic makeup of the original tumor. If successful, this approach could allow doctors to test different drugs on a patient's organoids before choosing a treatment. The study involves 60 adults with suspected pancreatic cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could pave the way for personalized drug testing on patient-derived organoids, potentially improving treatment choices for pancreatic cancer.
What could go wrong
This is an early-stage, observational study focused on lab methods, not a treatment trial. It may not lead to direct patient benefits, and organoid growth from small biopsies may fail.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient over 18 years of age. * Patient undergoing echo-endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB). * Suspicion of pancreatic lesion * Patient able to receive and understand information relating to the research protocol and to give consent. * Patient affiliated to the French social security system. Exclusion Criteria: * Patient not programmed for endoscopy with certainty/suspicion of fine needle biopsy (EUS-FNB). * Patient undergoing echo-endoscopy and presenting a high risk that may prevent EUS-FNB. * Patient with degenerated Intraductal papillary mucinous neoplasm (IPMN) * Patient with acute pancreatitis within 4 weeks prior to EUS * Pregnant or breast-feeding patient * Patient under court protection. * Patient under guardianship or curatorship. * Patient in a situation of social vulnerability. * Patient under legal protection or unable to express his/her opposition.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pdac - pancreatic ductal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pdac - pancreatic ductal adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre d'Endoscopie Digestive

    RECRUITING

    Strasbourg, France

  • Department of hepato-gastroenterology

    RECRUITING

    Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.